Viral-vector therapies hold enormous promise, but adoption has been limited by genetic instability, undesirable immunogenicity, tight payload limits, and hard-to-scale CMC. We tackle these issues from day one by redesigning the vector itself. With an AI/ML-guided platform and in-house libraries, we engineer vectors that are optimized for genetic stability, balanced immunogenicity, larger payloads, and scalable GMP-ready process from the start. The aim is simple: help clinicians evaluate new treatments sooner so patients access next-generation options faster.